# Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients

> **NCT01402401** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 21 (actual)

## Conditions studied

- Advanced Gastric Cancer

## Interventions

- **DRUG:** AUY922
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT01402401
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-11
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2020-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01402401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01402401, "Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01402401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*